{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:13:34Z","timestamp":1784117614490,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"JSPS KAKENHI","award":["23K06731"],"award-info":[{"award-number":["23K06731"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50317-4","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:34:59Z","timestamp":1778862899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Establishment and characterization of NKMS-1, a novel mouse NK cell line"],"prefix":"10.1038","volume":"16","author":[{"given":"Yuya","family":"Miyakura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoka","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Katori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Sugamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"50317_CR1","doi-asserted-by":"publisher","first-page":"e20231222","DOI":"10.1084\/jem.20231222","volume":"221","author":"LL Lanier","year":"2024","unstructured":"Lanier, L. L. Five decades of natural killer cell discovery. J. Exp. Med. 221, e20231222 (2024).","journal-title":"J. Exp. Med."},{"key":"50317_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier, E. et al. Natural killer cell therapies. Nature 626, 727\u2013736 (2024).","journal-title":"Nature"},{"key":"50317_CR3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","volume":"9","author":"S Chen","year":"2024","unstructured":"Chen, S., Zhu, H. & Jounaidi, Y. Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal. Transduct. Target. Ther. 9, 302 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"50317_CR4","doi-asserted-by":"publisher","first-page":"1483884","DOI":"10.3389\/fonc.2024.1483884","volume":"14","author":"SK Nikkhoi","year":"2024","unstructured":"Nikkhoi, S. K., Li, G. & Hatefi, A. Natural killer cell engagers for cancer immunotherapy. Front. Oncol. 14, 1483884 (2024).","journal-title":"Front. Oncol."},{"key":"50317_CR5","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jcyt.2025.06.006","volume":"27","author":"S Rana","year":"2025","unstructured":"Rana, S. et al. CAR-NK cells to treat patients with cancer: a systematic scoping review of published studies and registered clinical trials. Cytotherapy 27, 1179\u20131189 (2025).","journal-title":"Cytotherapy"},{"key":"50317_CR6","doi-asserted-by":"publisher","first-page":"1550652","DOI":"10.3389\/fimmu.2025.1550652","volume":"16","author":"JH Guo","year":"2025","unstructured":"Guo, J. H. et al. Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells. Front. Immunol. 16, 1550652 (2025).","journal-title":"Front. Immunol."},{"key":"50317_CR7","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1093\/jimmun\/vkaf036","volume":"214","author":"S Ma","year":"2025","unstructured":"Ma, S., Yu, J. & Caligiuri, M. A. Natural killer cell-based immunotherapy for cancer. J. Immunol. 214, 1444\u20131456 (2025).","journal-title":"J. Immunol."},{"key":"50317_CR8","first-page":"652","volume":"8","author":"JH Gong","year":"1994","unstructured":"Gong, J. H., Maki, G. & Klingemann, H. G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8, 652\u2013658 (1994).","journal-title":"Leukemia"},{"key":"50317_CR9","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.3390\/cancers17121968","volume":"17","author":"H Klingemann","year":"2025","unstructured":"Klingemann, H. The natural killer cell line NK-92 and its genetic variants: impact on NK cell research and cancer immunotherapy. Cancers (Basel) 17, 1968. (2025).","journal-title":"Cancers (Basel)"},{"key":"50317_CR10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1084\/jem.153.3.545","volume":"153","author":"G Dennert","year":"1981","unstructured":"Dennert, G., Yogeeswaran, G. & Yamagata, S. Cloned cell lines with natural killer activity. Specificity, function, and cell surface markers. J. Exp. Med. 153, 545\u2013556 (1981).","journal-title":"J. Exp. Med."},{"key":"50317_CR11","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.4049\/jimmunol.128.5.2326","volume":"128","author":"CG Brooks","year":"1982","unstructured":"Brooks, C. G., Kuribayashi, K., Sale, G. E. & Henney, C. S. Characterization of five cloned murine cell lines showing high cytolytic activity against YAC-1 cells. J. Immunol. 128, 2326\u20132335 (1982).","journal-title":"J. Immunol."},{"key":"50317_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/0008-8749(82)90075-2","volume":"69","author":"E Kedar","year":"1982","unstructured":"Kedar, E., Ikejiri, B. L., Sredni, B., Bonavida, B. & Herberman, R. B. Propagation of mouse cytotoxic clones with characteristics of natural killer (NK) cells. Cell. Immunol. 69, 305\u2013329 (1982).","journal-title":"Cell. Immunol."},{"key":"50317_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.4049\/jimmunol.130.2.981","volume":"130","author":"R Suzuki","year":"1983","unstructured":"Suzuki, R., Handa, K., Itoh, K. & Kumagai, K. Natural killer (NK) cells as a responder to interleukin 2 (IL 2). I. Proliferative response and establishment of cloned cells. J. Immunol. 130, 981\u2013987 (1983).","journal-title":"J. Immunol."},{"key":"50317_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0022-1759(86)90213-9","volume":"94","author":"R Lafreniere","year":"1986","unstructured":"Lafreniere, R., Rosenstein, M. S. & Rosenberg, S. A. Optimal methods for generating expanded lymphokine activated killer cells capable of reducing established murine tumors in vivo. J. Immunol. Methods. 94, 37\u201349 (1986).","journal-title":"J. Immunol. Methods"},{"key":"50317_CR15","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1182\/blood-2004-11-4237","volume":"105","author":"SL DeHart","year":"2005","unstructured":"DeHart, S. L., Heikens, M. J. & Tsai, S. Jagged2 promotes the development of natural killer cells and the establishment of functional natural killer cell lines. Blood 105, 3521\u20133527 (2005).","journal-title":"Blood"},{"key":"50317_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/jb\/mvj153","volume":"140","author":"S Iizuka","year":"2006","unstructured":"Iizuka, S., Kaifu, T., Nakamura, A., Obinata, M. & Takai, T. Establishment and functional characterization of novel natural killer cell lines derived from a temperature-sensitive SV40 large T antigen transgenic mouse. J. Biochem. 140, 255\u2013265 (2006).","journal-title":"J. Biochem."},{"key":"50317_CR17","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.4049\/jimmunol.134.3.1623","volume":"134","author":"J Yodoi","year":"1985","unstructured":"Yodoi, J. et al. TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J. Immunol. 134, 1623\u20131630 (1985).","journal-title":"J. Immunol."},{"key":"50317_CR18","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1182\/blood.V92.4.1374","volume":"92","author":"J Tsuchiyama","year":"1998","unstructured":"Tsuchiyama, J. et al. Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma\/leukemia associated with Epstein-Barr virus infection. Blood 92, 1374\u20131383 (1998).","journal-title":"Blood"},{"key":"50317_CR19","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/sj.leu.2401769","volume":"14","author":"M Yagita","year":"2000","unstructured":"Yagita, M. et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14, 922\u2013930 (2000).","journal-title":"Leukemia"},{"key":"50317_CR20","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0145-2126(02)00055-3","volume":"26","author":"RAF MacLeod","year":"2002","unstructured":"MacLeod, R. A. F., Nagel, S., Kaufmann, M., Greulich-Bode, K. & Drexler, H. G. Multicolor-FISH analysis of a natural killer cell line (NK-92). Leuk. Res. 26, 1027\u20131033 (2002).","journal-title":"Leuk. Res."},{"key":"50317_CR21","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.bbmt.2014.05.004","volume":"20","author":"JS Miller","year":"2014","unstructured":"Miller, J. S. et al. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol. Blood Marrow Transpl. 20, 1252\u20131257 (2014).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"50317_CR22","doi-asserted-by":"publisher","first-page":"822298","DOI":"10.3389\/fimmu.2022.822298","volume":"13","author":"KE Ruppel","year":"2022","unstructured":"Ruppel, K. E., Fricke, S., K\u00f6hl, U. & Schmiedel, D. Taking lessons from CAR-T cells and going beyond: tailoring design and signaling for CAR-NK cells in cancer therapy. Front. Immunol. 13, 822298 (2022).","journal-title":"Front. Immunol."},{"key":"50317_CR23","doi-asserted-by":"publisher","first-page":"5224","DOI":"10.1038\/s41467-020-19094-0","volume":"11","author":"C Mark","year":"2020","unstructured":"Mark, C. et al. Cryopreservation impairs 3-D migration and cytotoxicity of natural killer cells. Nat. Commun. 11, 5224 (2020).","journal-title":"Nat. Commun."},{"key":"50317_CR24","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/oxfordjournals.humrep.a136103","volume":"10","author":"DY Gao","year":"1995","unstructured":"Gao, D. Y. et al. Prevention of osmotic injury to human spermatozoa during addition and removal of glycerol. Hum. Reprod. 10, 1109\u20131122 (1995).","journal-title":"Hum. Reprod."},{"key":"50317_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.imlet.2017.04.006","volume":"189","author":"V Jelen\u010di\u0107","year":"2017","unstructured":"Jelen\u010di\u0107, V., Lenarti\u0107, M., Wensveen, F. M. & Poli\u0107, B. NKG2D: a versatile player in the immune system. Immunol. Lett. 189, 48\u201353 (2017).","journal-title":"Immunol. Lett."},{"key":"50317_CR26","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3389\/fimmu.2018.00476","volume":"9","author":"A Zingoni","year":"2018","unstructured":"Zingoni, A. et al. NKG2D and its ligands: \u2018One for All, All for One\u2019. Front. Immunol. 9, 476 (2018).","journal-title":"Front. Immunol."},{"key":"50317_CR27","doi-asserted-by":"publisher","first-page":"e144195","DOI":"10.1172\/JCI144195","volume":"131","author":"JR Veatch","year":"2021","unstructured":"Veatch, J. R. et al. A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells. J. Clin. Invest. 131, e144195 (2021).","journal-title":"J. Clin. Invest."},{"key":"50317_CR28","doi-asserted-by":"publisher","first-page":"104912","DOI":"10.1016\/j.critrevonc.2025.104912","volume":"214","author":"F Zhang","year":"2025","unstructured":"Zhang, F., Samarkhazan, S., Pooraskari, H., Bayani, A. Beyond CAR-T: engineered NK cell therapies (CAR-NK, NKCEs) in next-generation cancer immunotherapy. Crit. Rev. Oncol. Hematol. 214, 104912 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"50317_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10555-007-9072-0","volume":"26","author":"JE Talmadge","year":"2007","unstructured":"Talmadge, J. E., Donkor, M. & Scholar, E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 26, 373\u2013400 (2007).","journal-title":"Cancer Metastasis Rev."},{"key":"50317_CR30","doi-asserted-by":"publisher","first-page":"104702","DOI":"10.1016\/j.critrevonc.2025.104702","volume":"210","author":"D Liu","year":"2025","unstructured":"Liu, D. et al. A comprehensive review on targeting diverse immune cells for anticancer therapy: beyond immune checkpoint inhibitors. Crit. Rev. Oncol. Hematol. 210, 104702 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"50317_CR31","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/onc.2009.416","volume":"29","author":"F Pag\u00e8s","year":"2010","unstructured":"Pag\u00e8s, F. et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29, 1093\u20131102 (2010).","journal-title":"Oncogene"},{"key":"50317_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.coi.2017.07.016","volume":"48","author":"MA Cox","year":"2017","unstructured":"Cox, M. A., Nechanitzky, R. & Mak, T. W. Check point inhibitors as therapies for infectious diseases. Curr. Opin. Immunol. 48, 61\u201367 (2017).","journal-title":"Curr. Opin. Immunol."},{"key":"50317_CR33","doi-asserted-by":"publisher","first-page":"1499663","DOI":"10.3389\/fimmu.2025.1499663","volume":"16","author":"R Liu","year":"2025","unstructured":"Liu, R. et al. Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families. Front. Immunol. 16, 1499663 (2025).","journal-title":"Front. Immunol."},{"key":"50317_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fcimb.2020.00049","volume":"10","author":"SJ Judge","year":"2020","unstructured":"Judge, S. J., Murphy, W. J. & Canter, R. J. Characterizing the dysfunctional NK cell: assessing the clinical relevance of exhaustion, anergy, and senescence. Front. Cell. Infect. Microbiol. 10, 49 (2020).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"50317_CR35","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.3390\/cancers13174263","volume":"13","author":"I Buckle","year":"2021","unstructured":"Buckle, I. & Guillerey, C. Inhibitory receptors and immune checkpoints regulating natural killer cell responses to cancer. Cancers (Basel). 13, 4263 (2021).","journal-title":"Cancers (Basel)"},{"key":"50317_CR36","doi-asserted-by":"publisher","first-page":"886440","DOI":"10.3389\/fonc.2022.886440","volume":"12","author":"M Gemelli","year":"2022","unstructured":"Gemelli, M. et al. Overcoming resistance to checkpoint inhibitors: natural killer cells in non-small cell lung cancer. Front. Oncol. 12, 886440 (2022).","journal-title":"Front. Oncol."},{"key":"50317_CR37","doi-asserted-by":"publisher","first-page":"e26529","DOI":"10.4161\/onci.26529","volume":"2","author":"K Nakamura","year":"2013","unstructured":"Nakamura, K. et al. NK-cell fratricide: dynamic crosstalk between NK and cancer cells. Oncoimmunology 2, e26529 (2013).","journal-title":"Oncoimmunology"},{"key":"50317_CR38","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","volume":"28","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat. Med. 28, 2133\u20132144 (2022).","journal-title":"Nat. Med."},{"key":"50317_CR39","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jcyt.2022.12.003","volume":"25","author":"H Klingemann","year":"2023","unstructured":"Klingemann, H. The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer. Cytotherapy 25, 451\u2013457 (2023).","journal-title":"Cytotherapy"},{"key":"50317_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1158\/2326-6066.CIR-15-0098","volume":"3","author":"LL Lanier","year":"2015","unstructured":"Lanier, L. L. NKG2D receptor and its ligands in host defense. Cancer Immunol. Res. 3, 575\u2013582 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"50317_CR41","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nri1199","volume":"3","author":"DH Raulet","year":"2003","unstructured":"Raulet, D. H. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3, 781\u2013790 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"50317_CR42","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.4049\/jimmunol.162.6.3148","volume":"162","author":"R Galandrini","year":"1999","unstructured":"Galandrini, R., Palmieri, G., Piccoli, M., Frati, L. & Santoni, A. Role for the Rac1 exchange factor Vav in the signaling pathways leading to NK cell cytotoxicity. J. Immunol. 162, 3148\u20133152 (1999).","journal-title":"J. Immunol."},{"key":"50317_CR43","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1084\/jem.188.3.549","volume":"188","author":"DD Billadeau","year":"1998","unstructured":"Billadeau, D. D. et al. The Vav-Rac1 pathway in cytotoxic lymphocytes regulates the generation of cell-mediated killing. J. Exp. Med. 188, 549\u2013559 (1998).","journal-title":"J. Exp. Med."},{"key":"50317_CR44","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.4049\/jimmunol.177.4.2349","volume":"177","author":"DB Graham","year":"2006","unstructured":"Graham, D. B. et al. Vav1 controls DAP10-mediated natural cytotoxicity by regulating actin and microtubule dynamics. J. Immunol. 177, 2349\u20132355 (2006).","journal-title":"J. Immunol."},{"key":"50317_CR45","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/ni1325","volume":"7","author":"JL Upshaw","year":"2006","unstructured":"Upshaw, J. L. et al. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat. Immunol. 7, 524\u2013532 (2006).","journal-title":"Nat. Immunol."},{"key":"50317_CR46","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1084\/jem.20150792","volume":"212","author":"Z Zhang","year":"2015","unstructured":"Zhang, Z. et al. DNAM-1 controls NK cell activation via an ITT-like motif. J. Exp. Med. 212, 2165\u20132182 (2015).","journal-title":"J. Exp. Med."},{"key":"50317_CR47","volume-title":"Signaling Mechanisms Regulating T Cell Diversity and Function","author":"MY Bilal","year":"2018","unstructured":"Bilal, M. Y. & Houtman, J. C. D. Transmission of T cell receptor-mediated signaling via the GRB2 family of adaptor proteins. in Signaling Mechanisms Regulating T Cell Diversity and Function (eds Soboloff, J. & Kappes, D. J.) (CRC Press\/Taylor & Francis, Boca Raton (FL), (2018)."},{"key":"50317_CR48","first-page":"101803","volume":"39","author":"F Malagrin\u00f2","year":"2024","unstructured":"Malagrin\u00f2, F., Puglisi, E., Pagano, L., Travaglini-Allocatelli, C. & Toto, A. GRB2: a dynamic adaptor protein orchestrating cellular signaling in health and disease. Biochem. Biophys. Rep. 39, 101803 (2024).","journal-title":"Biochem. Biophys. Rep."},{"key":"50317_CR49","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3389\/fimmu.2015.00141","volume":"6","author":"MY Bilal","year":"2015","unstructured":"Bilal, M. Y. & Houtman, J. C. D. GRB2 nucleates T cell receptor-mediated LAT clusters that control PLC-\u03b31 activation and cytokine production. Front. Immunol. 6, 141 (2015).","journal-title":"Front. Immunol."},{"key":"50317_CR50","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1038\/emboj.2011.74","volume":"30","author":"JA Ackermann","year":"2011","unstructured":"Ackermann, J. A., Radtke, D., Maurberger, A., Winkler, T. H. & Nitschke, L. Grb2 regulates B-cell maturation, B-cell memory responses and inhibits B-cell Ca2\u2009+\u2009signalling. EMBO J. 30, 1621\u20131633 (2011).","journal-title":"EMBO J."},{"key":"50317_CR51","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.immuni.2004.09.007","volume":"21","author":"B Stork","year":"2004","unstructured":"Stork, B. et al. Grb2 and the non-T cell activation linker NTAL constitute a Ca2+-regulating signal circuit in B lymphocytes. Immunity 21, 681\u2013691 (2004).","journal-title":"Immunity"},{"key":"50317_CR52","doi-asserted-by":"publisher","first-page":"pe49","DOI":"10.1126\/scisignal.2003576","volume":"5","author":"AA Belov","year":"2012","unstructured":"Belov, A. A. & Mohammadi, M. Grb2, a double-edged sword of receptor tyrosine kinase signaling. Sci. Signal. 5, pe49 (2012).","journal-title":"Sci. Signal."},{"key":"50317_CR53","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.4049\/jimmunol.2300771","volume":"212","author":"EA Deborah","year":"2024","unstructured":"Deborah, E. A., Nabekura, T., Shibuya, K. & Shibuya, A. THEMIS2 impairs antitumor activity of NK cells by suppressing activating NK receptor signaling. J. Immunol. 212, 1819\u20131828 (2024).","journal-title":"J. Immunol."},{"key":"50317_CR54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jim.2004.08.008","volume":"294","author":"G Alter","year":"2004","unstructured":"Alter, G., Malenfant, J. M. & Altfeld, M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods. 294, 15\u201322 (2004).","journal-title":"J. Immunol. Methods"},{"key":"50317_CR55","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/gt.2008.90","volume":"15","author":"S Yang","year":"2008","unstructured":"Yang, S. et al. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther. 15, 1411\u20131423 (2008).","journal-title":"Gene Ther."},{"key":"50317_CR56","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0022-1759(83)90438-6","volume":"64","author":"C Korzeniewski","year":"1983","unstructured":"Korzeniewski, C. & Callewaert, D. M. An enzyme-release assay for natural cytotoxicity. J. Immunol. Methods. 64, 313\u2013320 (1983).","journal-title":"J. Immunol. Methods"},{"key":"50317_CR57","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/cyto.990160109","volume":"16","author":"L Hatam","year":"1994","unstructured":"Hatam, L., Schuval, S. & Bonagura, V. R. Flow cytometric analysis of natural killer cell function as a clinical assay. Cytometry 16, 59\u201368 (1994).","journal-title":"Cytometry"},{"key":"50317_CR58","doi-asserted-by":"publisher","first-page":"11856","DOI":"10.1038\/ncomms11856","volume":"7","author":"T Kuchimaru","year":"2016","unstructured":"Kuchimaru, T. et al. A luciferin analogue generating near-infrared bioluminescence achieves highly sensitive deep-tissue imaging. Nat. Commun. 7, 11856 (2016).","journal-title":"Nat. Commun."},{"key":"50317_CR59","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Karik\u00f3","year":"2005","unstructured":"Karik\u00f3, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165\u2013175 (2005).","journal-title":"Immunity"},{"key":"50317_CR60","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1182\/blood-2005-07-2797","volume":"107","author":"LL Veinotte","year":"2006","unstructured":"Veinotte, L. L., Greenwood, C. P., Mohammadi, N., Parachoniak, C. A. & Takei, F. Expression of rearranged TCRgamma genes in natural killer cells suggests a minor thymus-dependent pathway of lineage commitment. Blood 107, 2673\u20132679 (2006).","journal-title":"Blood"},{"key":"50317_CR61","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/0092-8674(93)90112-4","volume":"72","author":"S Itohara","year":"1993","unstructured":"Itohara, S. et al. T cell receptor delta gene mutant mice: independent generation of alpha beta T cells and programmed rearrangements of gamma delta TCR genes. Cell 72, 337\u2013348 (1993).","journal-title":"Cell"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50317-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50317-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50317-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:02:30Z","timestamp":1784116950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50317-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50317"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50317-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments in this study were performed under protocols approved by the Miyagi Cancer Center Animal Care and Use Committee (permission number: AE.23.08).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"22176"}}